CFMG & Wellpath in California — a documentary investigation · Article 087 of 100 · Series 9 — Regulators, cross-forum identity and the 2026 architecture

The Right to Leave in Modern California CPOM Enforcement

Published

20 September 2026, 6:00 PM PT

Content last changed

25 September 2026

Public-evidence cutoff

25 September 2026

Sources checked

25 September 2026

Record through

25 September 2026

Editorial status

Public-source editorial review complete

Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.

Executive finding#

A professional corporation can appear independent on paper while being structurally dependent on a management organization. California's 2026 Attorney General filings have made that point unusually explicit. In the Art Center dispute, the Attorney General argued that contractual power allowing an unlicensed MSO to replace the physician owner can amount to effective control and that a physician owner's inability to replace the MSO without risking loss of the practice can create undue control. The Carbon Health settlement announced later in 2026 likewise targeted owner-replacement and management-control provisions in a friendly-PC model.

Those authorities do not decide the CFMG–Wellpath relationship. The CFMG-specific stock-transfer agreement has not been located in the public record in the public record. That absence is precisely why the Right-to-Leave test has become one of the most important unresolved questions in the investigation.

The test asks not simply whether CFMG may terminate an MSA in contract language, but whether it can do so as a practical professional corporation and remain intact: retain its physician ownership, continue contracts, preserve records and systems, access working capital, maintain insurance, employ clinicians, retain credentials, and continue patient care. If the answer is yes, independence is strengthened. If the MSO can effectively replace the owner or make departure economically equivalent to surrendering the practice, control concerns become stronger.

I. Formal termination rights and practical exit rights are different#

Contracts often contain termination clauses. A party may technically have a right to terminate for breach, convenience, insolvency, or other events.

That tells only part of the story.

A professional corporation may depend on the MSO for:

• payroll;
• accounts receivable;
• billing;
• HR;
• IT;
• EHR access;
• data storage;
• credentialing administration;
• insurance;
• claims management;
• vendor contracts;
• office/facility infrastructure;
• financing;
• legal services;
• recruiting;
• compliance;
• quality systems.

If termination causes all of those functions to disappear immediately, a nominal right to leave may have little practical value unless transition rights exist.

II. Ownership consequences are more important than inconvenience#

Operational dependence alone does not necessarily violate CPOM. Many businesses depend heavily on vendors.

The structural concern becomes more serious when leaving the MSO affects ownership of the professional corporation itself.

If the physician owner can be replaced by the MSO, or if terminating the MSO triggers a forced stock transfer to a physician selected by the MSO, the physician's formal ownership may not reflect practical control.

That is the core of the Attorney General's recent structural analysis.

III. Why the CFMG stock-transfer reference matters#

The 2019 assignment of the CFMG MSA expressly references related or incidental stock-transfer restriction agreements.

This establishes that stock-transfer instruments were part of the transaction architecture.

It does not reveal their terms.

The missing agreement could materially strengthen either side of the investigation.

A conventional succession restriction designed to keep shares in the hands of qualified physicians could strengthen the lawful structure.

A provision giving the MSO broad power to compel transfer and select a successor could materially strengthen structural-control concerns.

The responsible conclusion is therefore agnostic until the document is obtained.

IV. The Right-to-Leave test has multiple dimensions#

1. Legal termination#

Can CFMG terminate the MSA, and under what conditions?

2. Ownership survival#

Does the shareholder retain shares after termination?

3. Successor selection#

Who selects a successor physician if transfer is required?

4. Data portability#

Can CFMG take patient records and operational data?

5. Revenue continuity#

Can CFMG continue billing and collecting receivables?

6. Workforce continuity#

Can CFMG retain employees and payroll capability?

7. Contract continuity#

Can county contracts continue or be assigned?

8. Insurance continuity#

Can CFMG maintain coverage independently?

9. Facility/system access#

Can clinicians continue operating during transition?

10. Financing#

Does CFMG have independent working capital or depend on manager funding?

Together these determine whether exit is realistic.

V. Fresno provides evidence of vendor replaceability—but not the full test#

Fresno County has selected different vendors for adjacent services and possesses procurement powers. That shows the County is not permanently bound to one enterprise for every service.

The County's ability to replace a contractor, however, is not the same as CFMG's ability to replace its MSO.

The two transitions involve different rights.

VI. Monterey provides a real-world transition laboratory#

Monterey's long CFMG/Wellpath relationship ended after a new procurement in December 2025. That creates a valuable before-and-after dataset for operational portability.

Investigators should examine:

• transfer of records;
• employee transition;
• system shutdown;
• continuity of medications and appointments;
• equipment ownership;
• open claims;
• quality records;
• credentialing data;
• county access systems.

This can show how portable the operating platform is when the government client replaces the contractor.

It still does not directly answer whether CFMG could replace Wellpath while retaining the county relationship.

VII. Bankruptcy provides a second stress test#

Wellpath's Chapter 11 altered upstream ownership and threatened continuity of management infrastructure. Yet CFMG continued as a nondebtor professional corporation and remained active in current contracts.

That suggests some degree of juridical resilience.

At the same time, the management relationship appears to have survived emergence, and current public records continue to identify Wellpath as CFMG's MSO.

Bankruptcy therefore did not naturally separate the parties enough to answer whether CFMG could independently leave.

VIII. The strongest evidence of independence would be an actual attempted exit#

Contracts and hypotheticals are helpful. A real event would be better.

If CFMG ever sought to replace its manager, records of that process would reveal:

• whether it could solicit alternatives;
• whether Wellpath could block the change;
• what happened to stock;
• what happened to contracts;
• how systems transitioned;
• whether physician governance controlled the decision.

No such public CFMG event has been located in the record reviewed.

IX. The Right-to-Leave test should not become an anti-integration doctrine#

A mature medical practice may reasonably choose long-term management integration because changing vendors is expensive and disruptive.

High switching costs do not automatically establish unlawful control.

The legal concern is not inconvenience. It is whether contractual rights or ownership mechanisms deprive physicians of genuine professional independence.

X. Financing can create practical leverage without proving illegality#

If an MSO provides deficit funding, working capital, insurance access, or financial guarantees, the professional corporation may become economically dependent.

Economic dependence can matter to practical autonomy, but it is not equivalent to professional control. The investigation must identify whether financing terms allow the MSO to influence professional decisions or ownership.

The CFMG financing documents therefore belong in the acquisition list.

XI. Records ownership is part of exit capacity#

The Medical Board identifies control of patient medical records as a professionally sensitive function. Data portability also determines whether a medical practice can leave an MSO without jeopardizing continuity of care.

The relevant distinction is:

• legal record custodian;
• EHR license holder;
• database administrator;
• export rights;
• post-termination access;
• retention obligations;
• County ownership rights in correctional settings.

XII. County contracts can both constrain and protect exit#

Correctional-health contracts often contain transition-assistance provisions, records-return obligations, data rights, staffing requirements, and County approval rights. Those terms can reduce lock-in by forcing continuity when vendors change.

They also mean CFMG's exit rights cannot be analyzed purely from the MSA. County consent and procurement law may matter.

XIII. The strongest lawful interpretation#

The strongest defense case is that stock-transfer restrictions exist to ensure continuous physician ownership, not to give Wellpath the practice. The MSO may have administrative rights necessary to protect its investment and continuity while the physician corporation retains professional authority. Long-term dependence may reflect efficiency and county-contract requirements rather than captivity.

Without the actual agreement, that interpretation remains plausible.

XIV. The strongest control interpretation#

The strongest investigative concern is that stock-transfer and management provisions could operate together so that CFMG's nominal physician owner cannot realistically terminate Wellpath without triggering replacement or losing control of the practice. Current California enforcement treats that kind of structure as highly relevant.

Without the actual agreement, that interpretation also remains plausible.

XV. The decisive documents#

1. CFMG stock-transfer restriction agreement.
2. Shareholder ledger and certificates.
3. MSA termination provisions and amendments.
4. Deficit Funding Loan Agreement.
5. Security/UCC documents.
6. Company Designee appointments.
7. Succession minutes for Fithian→Herr→Bazzel.
8. Data/EHR ownership agreements.
9. Insurance and claims agreements.
10. County transition-assistance clauses.
11. Any alternative-MSO solicitation or evaluation.
12. Post-emergence CFMG board ratification of management relationship.

XVI. Falsification test#

The structural-control concern would be materially weakened by a stock agreement showing that only independent physician-governance mechanisms can select successors, Wellpath cannot compel owner replacement for ordinary management disputes, and CFMG can terminate the MSO while retaining shares and operational continuity.

The lawful-independence thesis would be materially weakened by contractual terms giving Wellpath or its designee effective power to remove the physician owner, compel stock transfer, or prevent CFMG from changing managers without surrendering the practice.

XVII. Evidence assessment#

XVIII. Bottom line#

The Right-to-Leave question is the structural counterpart to the Demonstrated-Veto question.

The Demonstrated-Veto test asks who wins when CFMG and Wellpath disagree over a professional decision.

The Right-to-Leave test asks whether CFMG can end the management relationship and remain a physician-controlled practice.

Both are more probative than branding.

And both remain incompletely answered.

The next article examines Wellpath's own current description of CFMG—one of the clearest public representations available after emergence.

Selected primary public sources#

1. California Attorney General, Art Center amicus materials, Apr. 2026.
2. California Attorney General, Carbon Health settlement announcement, June 2026.
3. CFMG Management Services Agreement and 2019 assignment.
4. Current county contracts and transition provisions.

The right to leave after codification and the 2026 enforcement record#

The right-to-leave question this article develops received direct public treatment after the original research cutoff, from the state officer charged with enforcing the doctrine.

In the amicus brief filed on 30 March 2026 in Art Center Holdings, Inc. v. WCE CA Art, LLC, No. B338625, the Attorney General argued two propositions that together frame the exit question precisely. First, where an agreement gives an unlicensed corporation the right to replace the physician-owner of a practice with a physician of its choosing, the corporation effectively owns the practice. Second — and this is the half that speaks to exit — where the practice’s ostensible physician owner cannot replace the management organization without fear of losing ownership of the practice, the management organization has undue control.

The second proposition is the right to leave, stated as an enforcement position. It treats the practical cost of exit, not the formal existence of a termination clause, as the measure of control. An agreement that permits termination on paper while making termination ruinous in practice is, on the Attorney General’s reading, an agreement that denies the right to leave.

Two developments reinforce that this is an active enforcement posture rather than a theoretical one. A settlement announced on 26 June 2026 with Carbon Health Technologies, its affiliated professional medical corporations and a co-founder imposed $4.5 million in combined penalties and required structural reorganisation of a friendly-professional-corporation arrangement. A settlement concerning the corporate practice of dentistry was announced in May 2026. And Senate Bill 351, effective 1 January 2026, codified the underlying prohibition.

The qualifications matter as much as the developments. The amicus brief is advocacy and binds no one; the appeal is pending. The Attorney General filed in support of neither party, because both parties sought to weaken the prohibition. The California Medical Association’s brief of 13 April 2026 argues that such powers should be assessed on their facts rather than categorically. And none of this concerns CFMG, which is party to none of these matters. What the 2026 record supplies is a public statement of how California’s enforcement authority reads the exit question — against which the CFMG arrangement’s own exit terms, examined earlier in this article, can now be measured.

The clause nobody reads until it matters#

Every management services agreement contains a termination provision, and in ordinary commercial life nobody thinks about it. The parties intend to continue; the clause is boilerplate; the negotiation focuses on fees and scope.

In a professional-corporation arrangement that clause is the whole doctrine in miniature. California's corporate-practice prohibition exists to ensure that a licensed physician entity controls medical practice. An entity that cannot end its management relationship without losing its practice does not control anything, whatever the rest of the contract says.

That is why the right to leave is the sharpest available test of a friendly-professional-corporation structure, and why the Attorney General made it half of his 2026 argument.

The Attorney General's two propositions#

In the amicus brief filed on 30 March 2026 in Art Center Holdings, Inc. v. WCE CA Art, LLC, No. B338625, the Attorney General advanced two linked propositions.

The first concerns owner replacement: where an agreement gives an unlicensed corporation the right to replace the physician-owner of a practice with a physician of its choosing, the corporation effectively owns the practice.

The second concerns exit: where the practice's ostensible physician owner cannot replace the management organization without fear of losing ownership of the practice, the management organization has undue control.

The second proposition is the right to leave, stated as an enforcement position. Its structural move is to treat the practical cost of exit, not the formal existence of a termination clause, as the measure of control. An agreement that permits termination on paper while making termination ruinous in practice is, on this reading, an agreement that denies the right to leave.

The underlying trial court decision had found unlicensed practice where a succession agreement gave the holder discretion to transfer control from a physician it disagreed with to one of its choosing.

What makes exit expensive without prohibiting it#

The mechanisms are well known in the literature and none of them appears in a termination clause.

Infrastructure dependency. Where the manager holds the electronic health record, the billing system, the credentialing files and the scheduling platform, leaving means rebuilding an operating capability from nothing while continuing to deliver care.

Contract intermediation. Where county contracts were procured with manager support, or where the manager holds relationships with contracting agencies, exit threatens the revenue base rather than just the administrative layer.

Financial entanglement. Where the manager funds operating deficits, the professional corporation's solvency depends on the relationship continuing. A deficit-funding arrangement creates a debt that exit crystallises.

Personnel. Where the manager employs the administrative staff on whom clinical operations depend, exit means losing them.

Ownership linkage. Where stock-transfer restrictions tie the physician owner's shares to the management relationship, exit can threaten ownership directly. This is the mechanism the Attorney General's first proposition addresses, and it converts a commercial inconvenience into an existential one.

None of these is unlawful in itself. Their aggregate is what the Attorney General's brief describes as undue control.

What this arrangement's documents show#

The 2012 management services agreement contains provisions that bear on exit, and the analysis has to hold two things at once.

The agreement gives the professional corporation final contractual responsibility for physician staffing levels, reserves professional medical judgment, assigns it utilization-review guidelines, quality-assurance guidelines, physician corrective action, impaired-physician matters and pure-medical policies, and declares void any management act constituting the practice of medicine. Those are meaningful reservations and this article credits them.

The same agreement gives the manager accounting, payroll and tax, benefits, physician-employment documentation and policy administration, human resources, staffing analysis, compensation administration, billing, information technology, electronic health-record systems, county contracting support, compliance and licensing support, insurance and risk management, litigation support, purchasing, banking and budgeting.

A professional corporation that terminated this agreement would retain its licence, its physicians and its professional judgment. It would lose its billing, its records systems, its payroll, its human resources, its insurance programme and its county contracting support. Whether that constitutes a real right to leave is precisely the question the Attorney General's second proposition poses.

The instrument that would settle it#

The 2019 assignment by which the current manager took over expressly references related or incidental stock-transfer restriction instruments.

That reference is the most consequential lead in this investigation. Stock-transfer restrictions determine whether a physician owner can sell, to whom, on what trigger, and at what price. They are the mechanism by which the Attorney General's first proposition — owner replacement — operates, and they bear directly on whether exit threatens ownership.

A contract that references them is a contract acknowledging they exist. Their terms have not been located in the public record, and this article does not speculate about them.

The position opposing the Attorney General#

The California Medical Association filed an amicus brief on 13 April 2026 in the same appeal, arguing that a lay entity's power should be assessed on the facts of its exercise rather than treated as unlawful in itself, and warning against compliance standards dictated by worst-case constructions of contractual language.

That position deserves weight rather than dismissal. It comes from an organisation representing physicians, not management companies. On the California Medical Association's approach, a termination right that has never been tested, in a structure where physicians in fact exercise clinical judgment, would not establish a violation. Structural powers would be read against operating reality rather than against the worst case their language permits.

Two further features of the appeal belong in the account. Neither party asked the Court of Appeal to affirm the trial court's corporate-practice holding; both sought more permissive standards, which is why the Attorney General appeared in support of neither party. And the appeal is pending — the Second Appellate District has decided nothing, and neither brief is law.

Enforcement is active, and it is not about these entities#

The Attorney General's 2026 activity extended beyond briefing. A settlement announced on 26 June 2026 with Carbon Health Technologies, its affiliated professional medical corporations and a co-founder imposed $4.5 million in combined penalties and required structural reorganisation of a friendly-professional-corporation arrangement. A dental-practice settlement was announced in May 2026. Senate Bill 351, effective 1 January 2026, codified the underlying prohibition.

Those establish that California treats the arrangement type as an enforcement priority and will require structural change. None concerns the entities examined here, which are party to no located public enforcement matter.

Contrary evidence#

The professional corporation in this arrangement was not a debtor in the reorganisation, as a court-approved stipulation in Johnson v. County of Alameda, N.D. Cal. No. 3:23-cv-04069-CRB, Filing 76 of 23 March 2026, records. It holds county contracts in its own name. A Santa Barbara County staff report describes the structure accurately as the model California law contemplates. Sworn testimony in the El Dorado litigation records that its employees are paid by it and would not be considered management-company employees. No court has held the structure unlawful under section 2400.

What would resolve it#

The termination provisions in their operative form; any post-emergence amendment; the stock-transfer restriction instruments the 2019 assignment references; the deficit-funding arrangement and any security interest; the ownership of the electronic health record, billing systems and credentialing files; and the county contract assignment provisions.

The question is not whether a termination clause exists. It is what would happen if it were used — and that is answered by documents, not by the clause.

XIX. The right to leave became more concrete in California in 2026#

For years, corporate-practice analysis often focused on nominal ownership: whether the medical corporation's shares were held by a licensed physician. California's 2026 enforcement record makes clear why ownership alone is not enough. The Attorney General's Carbon Health case challenged a management structure not merely because of business integration, but because the state alleged that the management company could replace the physician owner and that the physician owner could not replace the management company without risking the medical practice itself.

That enforcement theory turns exit from an abstract contract clause into an empirical control test. A physician can own all voting shares on paper and still possess limited practical independence if terminating the MSO causes an automatic forced sale, loss of essential assets, loss of client contracts, loss of data, or replacement by a manager-selected successor. Conversely, a long-term exclusive management agreement is not unlawful merely because termination would be inconvenient or expensive. The question is whether the structure deprives the physician entity of meaningful control over its own professional practice.

The CFMG inquiry must therefore test exit across multiple dimensions rather than ask only whether the MSA contains a termination clause.

XX. Ten dimensions of practical exit#

The article identifies ten dimensions. Each should be treated as a separate evidentiary question.

1. Contractual termination#

Can CFMG terminate the management agreement for cause, without cause, at expiration, or upon specified events? What notice and cure periods apply? Does Wellpath possess symmetrical rights? Contractual termination is the threshold issue, but it is only the beginning.

2. Equity survival#

If CFMG terminates Wellpath, does the physician shareholder keep the shares? Any provision requiring sale, repurchase, redemption, or transfer because the management relationship ends is highly relevant. The same is true of options, proxies, powers of attorney, or succession rights triggered by termination.

3. Successor-manager freedom#

Can CFMG choose another management company? Does it need consent from Wellpath, a lender, a landlord, a client, or another party? Is there a noncompete, exclusivity provision, or transition restriction that makes replacement impractical?

4. Client-contract continuity#

County correctional-health contracts are often the professional corporation's principal revenue source. If a county contract is nonassignable or keyed to the integrated Wellpath platform, changing managers may require county consent or rebid. That dependence can be commercially significant without proving unlawful control.

5. Data portability#

Can CFMG obtain its patient records, quality data, credentialing files, employment data, billing information, policy repository, and audit logs in usable form? A nominal right to terminate has limited value if the practice cannot continue because its information infrastructure is trapped.

6. Workforce portability#

Can clinicians and administrative staff remain with CFMG after an MSO change? Are they employed by CFMG, Wellpath, or another entity? Do restrictive covenants, benefits, payroll systems, or recruiting arrangements impede transition?

7. Financing and working capital#

Can the professional corporation meet payroll, insurance, and operating expenses during transition? Deficit-funding or security arrangements may create substantial leverage. Leverage is not itself unlawful; the question is whether it effectively prevents exercise of professional rights.

8. Insurance and risk#

Can CFMG replace malpractice, general liability, employment-practices, cyber, and other insurance? Are historic claims retained by the old program? Does termination expose the PC to liabilities it cannot finance?

9. Brand, technology, and vendor continuity#

A practice may rely on enterprise email, EHR access, telehealth, pharmacy, scheduling, purchasing, credentialing, and vendor contracts. The ability to separate those services determines whether exit is operationally real.

10. Professional-governance continuity#

Most important, can CFMG retain its board, physician owner, professional committees, credentialing authority, and clinical policies through transition? If the governance system itself depends on the manager, the formal right to terminate may not preserve professional autonomy.

XXI. Exit costs are not the same thing as prohibited control#

A mature analysis must distinguish ordinary commercial lock-in from unlawful professional control. Long-term contracts often impose termination fees. Technology migrations are expensive. County consent may be required. Insurance markets can be difficult. Employees may prefer the incumbent benefits system. None of those facts alone establishes a corporate-practice violation.

The relevant question is whether the control consequences target the professional corporation's ownership or professional authority. A clause requiring reasonable transition costs is different from a clause that forces the physician owner to surrender shares if the MSO is terminated. A nonassignable software license is different from a manager's power to choose the successor physician owner. A county's right to approve a vendor is different from an MSO's right to veto professional succession.

This distinction prevents the Right-to-Leave test from becoming a generalized hostility to outsourcing.

XXII. The Carbon Health settlement is comparator evidence, not a verdict about CFMG#

California's Attorney General announced a 2026 settlement with Carbon Health and alleged that its MSO structure gave the management company improper power over physician-owned medical practices, including power over physician-owner replacement and constraints on replacing the MSO. Those allegations and settlement terms are highly relevant to the legal theory of exit.

They are not findings about CFMG. Different contracts, ownership structures, facts, and parties require independent proof. The correct use of the Carbon Health matter is to identify which contractual rights California's enforcement authorities consider significant, then compare those rights to authenticated CFMG instruments if and when they become available.

The analysis therefore must avoid syllogisms such as "Carbon Health had a stock-transfer arrangement; CFMG references a stock-transfer restriction; therefore CFMG is unlawful." The missing CFMG instrument is precisely why that conclusion cannot responsibly be made.

XXIII. The 2019 assignment makes the missing transfer document a central evidence target#

The 2019 assignment of the CFMG management agreement is unusually important because it references related or incidental instruments, including stock-transfer restriction arrangements. That reference establishes that such instruments were relevant to the management relationship. It does not establish their terms.

The CFMG-specific document should be reviewed for:

• who is party to it;
• which shares it covers;
• permitted transferees;
• mandatory-transfer events;
• valuation formula;
• who can initiate transfer;
• who selects the successor;
• whether management consent is required;
• whether termination of the MSA triggers transfer;
• whether death, disability, loss of license, employment termination, or retirement triggers transfer;
• any proxy, option, escrow, or power-of-attorney rights; and
• dispute-resolution and enforcement mechanisms.

Each term maps directly onto practical exit.

XXIV. Bankruptcy was a natural experiment in exit and continuity#

Chapter 11 could have disrupted the management relationship. Instead, public evidence strongly supports continuity of CFMG's relationship with Wellpath through emergence. That continuity is important but ambiguous.

One interpretation is affirmative choice: CFMG and Wellpath both considered the relationship valuable and continued it through restructuring. Another is structural dependence: the costs of separation, contractual obligations, client relationships, and integrated systems made continuation the only practical path. A third is simple legal continuity under plan assumption, with no contested choice at all.

The missing evidence is any CFMG corporate record showing whether physician governance considered alternatives, consented to assumption, negotiated amendments, or could have selected another MSO.

XXV. Grand Prairie narrows what "leave" means#

The Michigan Grand Prairie transition proves that a major Wellpath-associated correctional-health relationship could be unwound and replaced. The state moved from Grand Prairie/Wellpath service to VitalCore before Wellpath's bankruptcy. That is real portability evidence.

But Grand Prairie did not remain the same professional corporation serving the same client under a new MSO. The professional contractor itself was replaced. The event therefore establishes client portability, not necessarily manager portability.

That distinction makes the comparator more useful. It shows that operational transition is possible while leaving the central CFMG question intact: can the professional corporation itself keep its business and ownership while replacing the manager?

XXVI. County procurement both limits and protects autonomy#

County contracts can constrain exit because a change in management, subcontracting, ownership, staffing, or key personnel may require approval. But county procurement can also protect autonomy because the government client retains the ability to approve the contractor, demand continuity, and reject unauthorized substitutions.

For CFMG, the right to leave Wellpath may therefore depend partly on county consent. That is not management control; it is client control. A correct analysis should identify which consent belongs to the MSO and which belongs to the public customer.

This matters because a professional corporation might be legally free to change managers but unable to preserve a county contract without governmental approval. The resulting friction is real but arises from a different source of authority.

XXVII. Data ownership is one of the strongest practical indicators#

The Medical Board's corporate-practice guidance identifies control of patient medical records as an important professional issue. In a modern correctional system, however, "ownership" of records is not enough. Practical control includes access, extraction, interoperability, retention, cybersecurity, audit trails, and continuity.

A CFMG exit would be materially more realistic if the PC can obtain a complete, usable copy of patient and operational data and migrate to a successor platform without interrupting care. It would be materially less realistic if Wellpath exclusively controls the systems and can withhold or delay access.

The MSA, data-processing agreements, EHR terms, county contracts, and privacy agreements should therefore be read together. Data portability is both a continuity-of-care issue and an independence issue.

XXVIII. The strongest lawful exit model#

Under the strongest lawful model, CFMG's physician owner retains shares, its board retains professional authority, the MSA can be terminated under commercially reasonable terms, and CFMG can select a successor manager subject only to legitimate client and regulatory approvals. Data and workforce can transition, historic liabilities remain allocated by contract, and continuity-of-care obligations govern the handoff. Wellpath's extensive role reflects efficient outsourcing rather than captive control.

Evidence of an actual transition plan, a competitive MSO process, or a past CFMG rejection of management terms would strengthen that model.

XXIX. The strongest practical-control model#

Under the competing model, termination of the MSO triggers or threatens a transfer of physician ownership; the manager controls successor selection; essential data and systems cannot be ported; county contracts depend on the integrated platform; financing is conditioned on the management relationship; and the PC cannot continue without surrendering its practice economics. In that scenario, formal physician ownership may coexist with limited practical ability to exercise it.

That model requires authenticated CFMG-specific documents. It cannot be established from generic descriptions of friendly-PC structures.

XXX. Falsification#

The Right-to-Leave concern would be materially weakened by a transfer agreement granting no management succession rights, a termination clause allowing CFMG to replace the MSO without equity consequences, portable data and insurance provisions, and evidence of genuine alternative-manager authority.

The independence case would be materially weakened by compelled share-transfer terms tied to MSO termination, manager selection of the successor owner, unwaivable control over essential records, or other rights that make termination economically equivalent to loss of the practice.

Finding#

The Right-to-Leave test is valuable because it asks what happens when formal rights are exercised under stress. It does not presume that integration is unlawful. It asks whether the professional corporation can survive disagreement with its manager as a functioning professional practice.

The decisive CFMG question is not whether the MSA contains a termination clause. It is whether CFMG can terminate or replace its manager while preserving physician ownership, professional governance, client relationships, data, workforce, insurance, and operational continuity. California's 2026 enforcement record makes owner-replacement and manager-entrenchment rights especially important, but those comparator cases do not establish CFMG's terms. The CFMG-specific stock-transfer and exit instruments remain the controlling missing evidence.

Additional authorities#

• Medical Board of California, corporate-practice guidance under Business and Professions Code §§ 2052 and 2400.
• California Attorney General, Carbon Health settlement announced June 26, 2026.
• California Attorney General, April 1, 2026 CPOM amicus announcement.
• 2012 CFMG Management Services Agreement and 2019 assignment.
• Wellpath Chapter 11 and Grand Prairie/VitalCore transition materials.

XXXII. Exit should be measured at the moment of disagreement, not only at contract expiration#

Many agreements appear balanced while the parties are aligned. The practical test occurs when the professional corporation wants a result the manager opposes. If the PC can invoke termination, preserve ownership, obtain its data, retain or replace staff, and continue its client relationships, the exit right has substance. If invoking termination predictably destroys the practice, the formal clause may carry less practical weight.

This does not mean the law requires frictionless exit. The question is whether the consequences are ordinary transition costs or mechanisms that shift professional control to the manager.

XXXIII. Succession after death, disability, retirement, or loss of license is part of the same inquiry#

A professional corporation needs a lawful succession mechanism because a sole physician shareholder can die, retire, lose eligibility, or become unable to serve. A transfer restriction therefore is not suspicious merely because it compels a transfer under some conditions. The critical questions are who selects the successor, whether the successor must be independently qualified, whether valuation is fair, and whether the MSO can use a legitimate succession mechanism to control the professional owner.

The CFMG instrument should be evaluated in that context. A professionally necessary succession mechanism can be lawful and prudent. A mechanism giving an unlicensed manager unilateral owner-selection power raises a different issue.

Manager replacement and client replacement are different exits#

A county may decide to replace CFMG entirely. CFMG may decide to replace Wellpath while retaining the county contract. Wellpath may decide to leave a market. These are three different exits.

Grand Prairie primarily demonstrates client/provider replacement. The CFMG Right-to-Leave question concerns manager replacement while preserving the PC. County procurement records can prove the first; the MSA and stock-transfer instruments are necessary for the second.

Findings by confidence#

High confidence: California's current enforcement posture treats physician-owner succession and the ability to replace an MSO as significant indicators of control.

High confidence: the CFMG management architecture references transfer-related instruments whose specific terms have not been established in the public record reviewed.

High confidence: major correctional-health relationships can transition to different providers, as the Grand Prairie comparator demonstrates.

Unresolved: whether CFMG can replace Wellpath while retaining ownership, clients, data, workforce, and operational continuity.

XXXVII. The right to leave can be tested through a transition plan even before an actual exit occurs#

A professional corporation does not need to terminate its manager to prove that exit is real. A credible transition plan can provide substantial evidence. Such a plan would identify successor management options, data export procedures, employee transition, insurance replacement, county-consent requirements, vendor novation, financing, and continuity-of-care safeguards.

If CFMG has periodically evaluated alternative managers or maintained contingency plans, those records would support practical autonomy. If no transition is possible without manager-controlled assets or ownership consequences, the absence of a feasible plan becomes more significant.

XXXVIII. Transition assistance clauses deserve close attention#

A well-drafted management agreement often requires the outgoing manager to assist with handoff for a defined period. The scope, price, and enforceability of transition assistance can determine whether termination is realistic. Data return, vendor assignments, staff records, billing reconciliation, and credentialing support are especially important.

A clause that permits termination but allows immediate cutoff of every essential system is materially different from a clause that requires an orderly handoff. The operative CFMG agreement should be examined for those rights.

XXXIX. The public client may be the most important third party in an exit#

Correctional-health contracts are not ordinary medical-office leases. The County has constitutional and statutory obligations to maintain care, and it cannot tolerate a transition that interrupts medications, emergency response, or specialty access. Any manager replacement may therefore require detailed County coordination.

A strong Right-to-Leave analysis should separate constraints imposed for patient continuity and public procurement from constraints imposed by the MSO for corporate leverage. Both can make exit difficult, but only the second category directly bears on management control.

XL. Final adversarial checklist#

Before drawing a conclusion, ask: Can the physician owner keep the shares? Can CFMG select another MSO? Can it take its data? Can it finance payroll during transition? Can staff remain? Can insurance be replaced? Can county contracts continue with required consent? Can professional governance continue? Who controls the successor-owner process? Does termination trigger any compulsory equity event?

An answer to all ten questions would turn the Right-to-Leave concept from theory into evidence.

XLI. A manager can be difficult to replace for legitimate reasons#

The analysis must expressly recognize the strongest commercial defense. A manager that has spent years building systems, negotiating vendor contracts, hiring staff, and financing operations will be costly to replace. Long transition periods, notice requirements, reimbursement of unrecovered costs, or restrictions designed to protect confidential information can be legitimate. Difficulty is not the same as captivity.

The legal concern becomes sharper when the exit consequence reaches professional ownership or removes the physician entity's practical ability to continue as a practice. That is the line the evidence should test.

XLII. Valuation provisions can determine whether a transfer right is coercive#

If a succession agreement requires transfer of physician shares, the price matters. Fair-market-value purchase by an eligible successor can serve legitimate continuity purposes. A nominal or punitive valuation tied to termination of the MSO could create very different incentives. The valuation formula, appraisal process, dispute mechanism, and timing should therefore be examined together with the transfer trigger.

XLIII. Exit rights should be compared before and after bankruptcy#

A post-emergence amendment may alter termination, financing, or succession provisions. The Right-to-Leave analysis should compare prepetition and current terms rather than assuming continuity. If rights improved after restructuring, that is relevant counterevidence to a historical control thesis. If they became more restrictive, that matters in the opposite direction.

XLIV. Final falsification promise#

If the CFMG-specific transfer and termination documents show that physician ownership survives manager replacement and that CFMG can transition to another MSO under commercially reasonable terms, the analysis must say that the Right-to-Leave test is satisfied to the extent those documents prove it. If they show manager-controlled succession or practice-forfeiture consequences, the analysis must say the opposite with equal clarity.

XLV. The right to leave is ultimately a continuity-of-practice test#

The practical purpose of exit rights is not to reward corporate mobility. It is to ensure that the physician-owned practice can continue serving patients under professional control when the management relationship changes. That is why data, staff, insurance, financing, and client-consent provisions belong in the same analysis as stock transfer.

A transition that protects patients and preserves the professional corporation while allowing the manager to receive fair contractual compensation is consistent with meaningful autonomy. A transition mechanism that forces surrender of the practice itself raises a different concern. The operative documents, not generalized suspicion of management contracts, must decide which description fits CFMG.

Carbon Health and Aspen Dental as enforcement parallels#

Carbon Health (June 2026). The Attorney General’s complaint alleges that an unlicensed management company effectively owned and controlled affiliated physician practices through succession and option provisions, security interests in physician shares, consent rights and management authority over staffing, compensation, billing, records, equipment and advertising. The announced settlement requires restructuring so the management company cannot control or hold prohibited interests in the practices, with $4.4 million in company penalties and $100,000 against the co-founder. The Attorney General describes it as subject to court approval, and the DOJ-hosted judgment is captioned as proposed; this investigation has not located a later docket entry showing entry.

Aspen Dental (May 2026). A dentistry analogue, also announced subject to court approval. Its injunctive terms bar the support organization from choosing replacement professional owners or making termination of the support company functionally cost the professional owner the practice — the right-to-leave problem stated as a remedy. It is parallel professional-corporation enforcement, not medical precedent against CFMG.

Art Center remains pending. The Attorney General’s March 2026 amicus brief argues that when the physician owner cannot replace the MSO without risking loss of the practice, the MSO can hold undue control. The California Medical Association’s separate amicus brief urges a contextual, fact-dependent analysis. Neither is an appellate holding.

For CFMG, the right-to-leave test now has a concrete document target: the termination, post-termination and succession provisions that determine whether CFMG could replace Wellpath and keep its shares, contracts, workforce, records and county relationships. See the control-indicator matrix. Added 25 September 2026.